[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362368-105":59,"doc-detail-362368-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-molecular-and-functional-landscape-of-resistance-to-folfiri-chemotherapy-in-metastatic-colorectal-cancer","The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer","","FOLFIRI-based chemotherapy remains a standard option for metastatic colorectal cancer, yet benefits only about half of patients. Using patient-derived xenografts and tumoroid systems, the study dissects why responses vary, showing FOLFIRI resistance linked to innate immunity and mitochondrial metabolism gene upregulation and diminished POLD1 expression. Sensitive models display BRCAness-like traits with homologous recombination deficiency driven by low RAD51 abundance. RAD51 overexpression mitigates HR-related scars and chemotherapy damage, while ATM-mediated HR inhibition increases drug sensitivity, with predictive determinants validated in clinical samples.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-molecular-and-functional-landscape-of-resistance-to-folfiri-chemotherapy-in-metastatic-colorectal-cancer/362368/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-molecular-and-functional-landscape-of-resistance-to-folfiri-chemotherapy-in-metastatic-colorectal-cancer/362368.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is FOLFIRI response variable in metastatic colorectal cancer?","Question",{"text":112,"@type":113},"About half of patients benefit, and the study attributes variability to functional, non-genetic aspects of homologous recombination repair rather than straightforward genetic or epigenetic HR gene loss.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular feature characterizes FOLFIRI resistance models?",{"text":117,"@type":113},"Resistant models show transcriptional upregulation of innate immunity and mitochondrial metabolism genes together with reduced POLD1 expression.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the study’s findings link RAD51 to chemotherapy sensitivity?",{"text":121,"@type":113},"Sensitive models exhibit BRCAness-like genomic scars caused by low RAD51 recombinase abundance. Forcing RAD51 overexpression attenuates HR deficiency scars and chemotherapy-induced damage, while ATM blockade enhances drug sensitivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362368,1790240379,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ReseaRch aRticle  \nThe Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer   \nMarco Avolio1, Simonetta M. Leto1, Francesco Sassi1, Barbara Lupo1,2, Elena Grassi1,2, Irene Catalano1, Eugenia R. Zanella1, Valentina Vurchio1,2, Francesca Cottino1, Petros K. Tsantoulis3, Luca Lazzari4, Paolo Luraghi4, Martina Ferri1,2, Francesco Galimi1,2, Enrico Berrino1, Sara E. Bellomo1, Marco Viviani1,2, Alberto Sogari4,5, Gianluca Mauri4,6,7, Federica Tosi7, Federica Cruciani4, Andrea Sartore-Bianchi6,7, Salvatore Siena6,7, Felice Borghi1, Valter Torri8, Elena Élez9, 10, 11, Josep Tabernero9, 10, 11, Maria Nieva12, Clara Montagut11, 12, 13, Noelia Tarazona11, 14, Andrés Cervantes11, 14, Sabine Tejpar15, Alberto Bardelli4,5, Caterina Marchiò1, 16, Silvia Marsoni4, Andrea Bertotti1,2, and Livio Trusolino1,2  \nThe combination of 5-fluorouracil and irinotecan (FOLFIRI) remains a standard-of  \ncare treatment for metastatic colorectal cancer (mCRC) yet benefits only about half of patients. Using patient-derived xenografts, we investigated the biological underpinnings of this heterogeneous response. FOLFIRI-resistant models showed transcriptional upregulation of innate immunity and mitochondrial metabolism genes, together with reduced expression of the DNA polymerase POLD1 . Sensitive counterparts exhibited a BRCAness-like phenotype with genomic scars of homologous recombination (HR) deficiency, not caused by genetic or epigenetic loss of HR genes but by low abundance of the RAD51 recombinase. In tumoroids, forced RAD51 overexpression attenuated HR deficiency–related scars and chemotherapy-induced damage, whereas HR inhibition through ATM blockade enhanced drug sensitivity. The predictive relevance of key response determinants was validated in clinical samples. This work illuminates functional, nongenetic facets of BRCAness in mCRC and introduces actionable biomarkers and targets, offering prospects to improve clinical decision-making and broaden therapeutic options for chemorefractory patients.  \nSIgnIFICanCe: FOLFIRI response biomarkers in mCRC are lacking. Evidence in patient-derived xenografts, tumoroids, and patients shows that chemosensitivity arises from functional relaxation, rather than (epi)genetic inactivation, of the HR DNA repair pathway. Integrative analyses yield a chemopredictive algorithm centered on the expression of the RAD51 recombinase, with potential torefine patient stratification.  \nintRoduction  \nColorectal cancer ranks as the third most prevalent cancer globally, accounting for approximately 10% of all cancer cases and standing as the second leading cause of cancer-related deaths worldwide (1) . Around 20% of colorectal cancers present as metastatic at the time of initial diagnosis, and nearly half of patients with localized colorectal cancer will eventually develop metastases (2, 3) . Systemic chemotherapy is the primary treatment modality for patients with microsatellite stable (MSS) metastatic disease who are not eligible for surgery, with sequential or combined administration of fluoropyrimidines, oxaliplatin, and irinotecan resulting in median overall survival (OS) ranging from 18 to 26 months (4) . However, the current paradigm of cytotoxic treatments follows a “one-size-fits-all” approach, with only a subset of patients achieving a clinical benefit, whereas many endure unnecessary exposure to the toxic effects of treatment.  \n1Candiolo Cancer Institute – FPO IRCCS, Torino, Italy. 2Department of Oncology, Candiolo Satellite, University of Torino, Torino, Italy. 3Faculty of Medicine, Université de Genève, Geneva, Switzerland. 4 IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy. 5Department of Oncology, Molecular Biotechnology Center, University of Torino, Torino, Italy.  \n6Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy. 7Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy. 8Mario Ne","cbCaihIwBjziX1of","https://ap.wps.com/l/cbCaihIwBjziX1of","pdf",15476792,26,"English","# Introduction\n## Chemotherapy benefit heterogeneity and clinical need for biomarkers\n## Prior biomarker research and limitations\n## Study focus on functional, non-genetic BRCAness","[{\"question\":\"Why is FOLFIRI response variable in metastatic colorectal cancer?\",\"answer\":\"About half of patients benefit, and the study attributes variability to functional, non-genetic aspects of homologous recombination repair rather than straightforward genetic or epigenetic HR gene loss.\"},{\"question\":\"What molecular feature characterizes FOLFIRI resistance models?\",\"answer\":\"Resistant models show transcriptional upregulation of innate immunity and mitochondrial metabolism genes together with reduced POLD1 expression.\"},{\"question\":\"How do the study’s findings link RAD51 to chemotherapy sensitivity?\",\"answer\":\"Sensitive models exhibit BRCAness-like genomic scars caused by low RAD51 recombinase abundance. Forcing RAD51 overexpression attenuates HR deficiency scars and chemotherapy-induced damage, while ATM blockade enhances drug sensitivity.\"}]","The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer | PDF",1790147398,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f913bdbbf7455b526bd1095746f1db7.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90500e5efd953a8d753007a3b65785f6.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b869de1f256ce4de05ede1448827795.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7353ef7737cae265f534aa8998600dd8.webp",980,1311]